RNAi therapeutics: Principles, prospects and challenges

被引:667
|
作者
Aagaard, Lars [1 ]
Rossi, John J. [1 ]
机构
[1] City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Duarte, CA 91010 USA
关键词
siRNA; shRNA; RNAi; RNA interference; antisense; miRNA; RISC;
D O I
10.1016/j.addr.2007.03.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other antisense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression. Despite the excitement about this remarkable biological process for sequence specific gene regulation, there are a number of hurdles and concerns that must be overcome prior to making RNAi a real therapeutic modality, which include off-target effects, triggering of type I interferon responses, and effective delivery in vivo. This review discusses mechanistic aspects of RNAi, the potential problem areas and solutions and therapeutic applications. It is anticipated that RNAi will be a major therapeutic modality within the next several years, and clearly warrants intense investigation to fully understand the mechanisms involved. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:75 / 86
页数:12
相关论文
共 50 条
  • [1] RNAi-based therapeutics-current status, challenges and prospects
    Tiemann, Katrin
    Rossi, John J.
    EMBO MOLECULAR MEDICINE, 2009, 1 (03) : 142 - 151
  • [2] Bioengineered baculoviruses as new class of therapeutics using micro and nanotechnologies: Principles, prospects and challenges
    Paul, Arghya
    Hasan, Anwarul
    Rodes, Laetitia
    Sangaralingam, Mugundhine
    Prakash, Satya
    ADVANCED DRUG DELIVERY REVIEWS, 2014, 71 : 115 - 130
  • [3] Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
    Zhou, Jiehua
    Shum, Ka-To
    Burnett, John C.
    Rossi, John J.
    PHARMACEUTICALS, 2013, 6 (01): : 85 - 107
  • [4] RNAi therapeutics
    Limmer, S
    JOURNAL OF BIOTECHNOLOGY, 2005, 118 : S69 - S69
  • [5] Physiologically based pharmacokinetic (PBPK) modeling of RNAi therapeutics: Opportunities and challenges
    Fairman, Kiara
    Li, Miao
    Ning, Baitang
    Lumen, Annie
    BIOCHEMICAL PHARMACOLOGY, 2021, 189
  • [6] siRNA therapeutics: insights, challenges, remedies and future prospects
    Khan, Saba
    Rehman, Urushi
    Parveen, Neha
    Kumar, Shobhit
    Baboota, Sanjula
    Ali, Javed
    EXPERT OPINION ON DRUG DELIVERY, 2023, 20 (09) : 1167 - 1187
  • [7] Oligonucleotide analogs as potential therapeutics: Challenges and prospects.
    Iyer, RP
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U237 - U237
  • [8] Prospects, challenges and current status of RNAi through insect feeding
    Kunte, Nitish
    McGraw, Erin
    Bell, Sydney
    Held, David
    Avila, Luz-Adriana
    PEST MANAGEMENT SCIENCE, 2020, 76 (01) : 26 - 41
  • [9] The business of RNAi therapeutics
    Haussecker, Dirk
    HUMAN GENE THERAPY, 2008, 19 (05) : 451 - 462
  • [10] The world of RNAi therapeutics
    Manoharan, M.
    FEBS OPEN BIO, 2019, 9 : 50 - 50